Charles C. Wykoff, MD, PhD
Charles C. Wykoff, MD, PhD, is a board-certified medical and surgical retina specialist and ophthalmologist with Retina Consultants of Texas.
Articles
Future Research Directions for Revakinagene Taroretcel in MacTel
Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of patient groups for the rare condition.
How Revakinagene Taroretcel Can Benefit Patients With MacTel: Dr Charles Wykoff
The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, said.
Revakinagene Taroretcel Approval Addresses Unmet Need in MacTel
Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy indicated for the treatment of macular telangiectasia type 2 (MacTel).
